UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome

Blood, 2021-07, Vol.137 (26), p.3676-3681

2021

Volltextzugriff (PDF)

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Journal of clinical oncology, 2013-07, Vol.31 (20), p.2540-2547

2013

Volltextzugriff (PDF)

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Blood, 2015-03, Vol.125 (12), p.1932-1935

2015

Volltextzugriff (PDF)

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis

Blood, 2014-08, Vol.124 (8), p.1296-1299

2014

Volltextzugriff (PDF)

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

Haematologica (Roma), 2016-02, Vol.101 (2), p.e69-e71

2016

Volltextzugriff (PDF)

Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies

Histopathology, 2011-01, Vol.58 (1), p.90-105

de Tute, Ruth M

2011

Volltextzugriff (PDF)

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

Journal of clinical oncology, 2023-08, Vol.41 (23), p.3945-3955

2023

Volltextzugriff (PDF)

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Journal of clinical oncology, 2022-09, Vol.40 (25), p.2889-2900

2022

Volltextzugriff (PDF)

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

The New England journal of medicine, 2008-08, Vol.359 (6), p.575-583

2008

Volltextzugriff (PDF)

Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial

Bone marrow transplantation (Basingstoke), 2024-03, Vol.59 (3), p.431-434

2024

Volltextzugriff (PDF)

Bortezomib consolidation post‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse

British journal of haematology, 2019-06, Vol.185 (5), p.948-951

2019

Volltextzugriff (PDF)

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service

Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.54-60

2016

Volltextzugriff (PDF)

B‐cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle

British journal of haematology, 2007-11, Vol.139 (4), p.600-604

2007

Volltextzugriff (PDF)

Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells

Clinical lymphoma, myeloma and leukemia, 2013-04, Vol.13 (2), p.211-213

2013

Volltextzugriff (PDF)

Reply to M. Roschewski et al

Journal of clinical oncology, 2014-02, Vol.32 (5), p.476-477

2014

Volltextzugriff (PDF)

Defining IgM multiple myeloma

American journal of hematology, 2011-08, Vol.86 (8), p.717-717

2011

Volltextzugriff (PDF)

Translocation t(14;16) in IgM multiple myeloma

British journal of haematology, 2011-11, Vol.155 (3), p.402-403

2011

Volltextzugriff (PDF)

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

Blood, 2022-11, Vol.140 (Supplement 1), p.7032-7033

2022

Volltextzugriff (PDF)

Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK’s Haematological Malignancy Research Network

Cancer epidemiology, 2024-02, Vol.88, p.102513-102513, Article 102513

2024

Volltextzugriff (PDF)

PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia

British journal of haematology, 2024-08

2024

Volltextzugriff (PDF)

Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine Trial

Blood, 2023-11, Vol.142 (Supplement 1), p.881-881

2023

Volltextzugriff (PDF)

1 – 25 von 113

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SeriePlos Medicine

ThemaBone Marrow

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(110)

Publikationsform

Sprache

Englisch
(113)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Humans
(25)
Hematology
(21)
Female
(14)
Male
(12)
Middle Aged
(11)
Aged
(10)
Oncology
(10)
Myeloma
(9)
Multiple Myeloma - Drug Therapy
(8)
Adult
(7)
Flow Cytometry
(7)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Multiple Myeloma - Diagnosis
(6)
Hematologic And Hematopoietic Diseases
(5)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(5)
Multiple Myeloma
(5)
Multiple Myeloma - Pathology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Free E-Journals
(88)
Standalone journals
(70)
Ovid SocietyJournals and Single Titles
(35)
MEDLINE
(25)
Wiley Online Library
(15)
Wiley Online Library
(15)
Access via ScienceDirect (Elsevier)
(15)
Ingenta.com
(6)
IngentaConnect Journals
(5)
BMJ_英国医学会期刊
(3)
Ebook Central Perpetual and DDA
(2)
eBooks on EBSCOhost
(2)
Nexis Uni
(1)
Nature
(1)

9 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial

Bortezomib consolidation post‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial

B‐cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle

Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells

Reply to M. Roschewski et al

Defining IgM multiple myeloma

Translocation t(14;16) in IgM multiple myeloma

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK’s Haematological Malignancy Research Network

PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia

Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine Trial

Aktive Filter

Suchergebnisse filtern